Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER PAD colchicine trial in peripheral artery disease
NL-OMON59480Phase 3Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of colchicine in arteriosclerosis obliterans (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Primary composite endpoint. Started Nov 2024; status: recruiting.
02
Drugs
colchicine
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON59480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59480.